The approval is supported by data from the DESTINY-Gastric04 Phase III trial.

Earlier this week, Daiichi Sankyo and AstraZeneca received approval in China for ENHERTU as the first HER2-directed antibody-drug conjugate for second-line treatment of HER2 positive metastatic ...

Japanese drugmaker Daiichi Sankyo has appointed Veronika Rozehnal to succeed Jürgen Müller as the Head of the Translational ...

If you are wondering whether Daiichi Sankyo Company is attractively priced or not, you will want to see how its current ...

CNW/ - (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in ...

When Daiichi Sankyo decided to move to its new U.S. headquarters in Basking Ridge, bringing more than 700 jobs in the process, it sought two things: to consolidate its offices in Parsippany and Edison ...

Daiichi Sankyo has expanded its presence in Canada with the official opening of its permanent headquarters in Toronto, ...

Pharmaceutical Executive: What was Daiichi Sankyo's strategy for preparing for the JP Morgan Healthcare Conference? Ken ...

Daiichi Sankyo receives Prime Minister’s Award for Japan Medical Research and Development Grand Prize: Tokyo Tuesday, January 20, 2026, 17:00 Hrs [IST] Daiichi Sankyo has receiv ...

Daiichi Sankyo and GENESIS Pharma will distribute and commercialize quizartinib, brand name VANFLYTA, in 13 markets.

Daiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to press reports. Citing Nikkei Business, Reuters reported that the final price is ...